Progesterone 400 mg pessaries

Country: Ireland

Bahasa: Inggeris

Sumber: HPRA (Health Products Regulatory Authority)

Bahan aktif:

Progesterone

Boleh didapati daripada:

Actavis Group PTC ehf

Kod ATC:

G03DA; G03DA04

INN (Nama Antarabangsa):

Progesterone

Dos:

400 milligram(s)

Borang farmaseutikal:

Pessary

Jenis preskripsi:

Product subject to prescription which may not be renewed (A)

Kawasan terapeutik:

Pregnen (4) derivatives; progesterone

Status kebenaran:

Not marketed

Tarikh kebenaran:

2017-03-31

Risalah maklumat

PACKAGE LEAFLET: INFORMATION FOR THE USER
PROGESTERONE 400 MG PESSARIES
Progesterone
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Progesterone is and what it is used for
2.
What you need to know before you use Progesterone
3.
How to use Progesterone
4.
Possible side effects
5.
How to store Progesterone
6.
Contents of the pack and other information
1.
WHAT PROGESTERONE IS AND WHAT IT IS USED FOR
Progesterone contains progesterone which is a natural, female sex
hormone, produced in the body.
Progesterone is for women who need extra progesterone while undergoing
treatment in an Assisted
Reproductive Technology (ART) programme.
Progesterone acts on the lining of the womb and it helps you to become
and to stay pregnant when
you are treated for infertility.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE PROGESTERONE
DO NOT USE PROGESTERONE:
-
if you are allergic to progesterone or any of the other ingredients of
this medicine (listed in
section 6),
-
have unusual vaginal bleeding that has not been evaluated by the
doctor,
-
have known or suspected tumour that is hormone sensitive,
-
have porphyria disorders (a group of inherited or acquired disorders
of certain enzymes),
-
have or have had blood clots in the legs, lungs, eyes or elsewhere in
the body,
-
currently have or have had severe liver problems.
-
have a miscarriage and your physician suspects some tissue is still in
the uterus or pregnancy
outside of the womb.
WARNINGS AND PRECAUTIONS
Take special care and tell your doctor straight aw

Ciri produk

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Progesterone 400 mg pessaries
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each pessary contains 400 mg progesterone
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Pessary
Off-white, approximately 10mm x 30mm, torpedo shaped pessary.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Progesterone is indicated for luteal phase support as part of an
Assisted Reproductive Technology (ART) treatment for
women.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adults_
One 400 mg pessary administered vaginally twice a day starting at
oocyte retrieval. The administration of Progesterone
should be continued for 38 days, if pregnancy has been confirmed.
_Paediatric population_
There is no relevant use of Progesterone in the paediatric population.
_Elderly_
No clinical data have been collected in patients over age 65.
_Use in special populations_
There is no experience with use of Progesterone in patients with
impaired liver or renal function.
Method of administration
For vaginal insertion.
4.3 CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients
listed in section 6.1.
Undiagnosed vaginal bleeding.
Known or suspected progesterone sensitive malignant tumours.
Porphyria.
Known missed abortion or ectopic pregnancy.
Active arterial or venous thromboembolism or severe thrombophlebitis,
or a history of these events.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_5_
_/